Developer docs
API playgroundTry for free, no card

Search company profiles

Bionovis

Full company profile

uuid000anfk

Namestring
Bionovis
Legal namestring
BIONOVIS S/A – COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACÊUTICA
Websiteurl
bionovis.com.br
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Bionovis is a privately held Brazilian pharmaceutical biotechnology company founded in 2012 as a joint venture of four domestic laboratories — Aché, EMS, Hypera Pharma, and União Química. The company develops and manufactures biological and biosimilar medicines using mammalian cell culture technology at an industrial-scale facility in Valinhos, São Paulo, which houses a pilot plant (bioreactors up to 200 L), a quality control laboratory, and three production lines (one continuous perfusion, two fed-batch using single-use reactors) totaling more than 20,000 L of bioreactor volume and capacity to produce up to 250 kg of protein per year across ten biopharmaceuticals. Its marketed portfolio spans monoclonal antibodies (bevacizumab, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim), addressing oncology, autoimmune disease, neurology, ophthalmology, and hematology.

The revenue model rests on three pillars: (i) supply of biosimilars to the Brazilian public healthcare system (SUS) under Productive Development Partnerships (PDPs) with the Ministry of Health, technology-transfer-licensed from global originators (Samsung Bioepis, Sandoz, Biocon, Dr. Reddy's, Fresenius Kabi, J&J/Janssen, Merck); (ii) private-market commercialization through commercial partnerships with INTAS and mAbxience; and (iii) contract manufacturing organization (CMO) services at the Valinhos plant. Notable commercial brands include Bevanovis® (bevacizumab, launched 2025) and Pegtima® (pegfilgrastim, launched 2023). The company is ANVISA-certified, claims more than 1 million patients impacted and 19 million vials/syringes delivered cumulatively since founding, and is pursuing in-house pipeline candidates BNV-007 and BNV-008 alongside new 2026 partnerships for pertuzumab and additional biosimilars targeting expansion into Latin America and other regulated markets.

Short descriptiontext

Bionovis is a Brazilian pharmaceutical biotech (founded 2012 as a JV of Aché, EMS, Hypera Pharma, and União Química) that develops and manufactures biological and biosimilar medicines at its ANVISA-certified Valinhos facility, supplying SUS, private healthcare, and CMO clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersValinhos, Brazil
HQ citystring
Valinhos
HQ countrystring
Brazil
HQ regionstring
Latin America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biological medicines, biosimilar production, monoclonal antibodies, pharmaceutical manufacturing, contract manufacturing
Industry2 codes
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Public Healthcare Product Sales (SUS)
TypeSubscription Recurring
Description

Bionovis supplies biological and biosimilar medicines to the Brazilian public healthcare system (SUS) through Productive Development Partnerships (PDPs) with the Ministry of Health. Products include infliximab, interferon beta-1a, etanercept, trastuzumab, golimumab, rituximab, adalimumab, bevacizumab, nivolumab, pertuzumab, aflibercept, eculizumab, and pegfilgrastim.

bionovis.com.br
2Private Market Commercialization
TypeTransaction Fee
Description

Commercial partnerships in the private sector through INTAS and mAbxience for distribution and sale of biopharmaceutical products in the Brazilian private market.

bionovis.com.br
3Contract Manufacturing (CMO Services)
TypeProfessional Services
Description

Bionovis offers contract manufacturing organization services at its industrial plant in Valinhos, São Paulo, enabling pharmaceutical companies to outsource large-scale manufacturing of biopharmaceuticals or production of clinical batches for scientific trials.

Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Bevanovis (bevacizumab)
Description

Bevanovis is a monoclonal antibody that inhibits VEGF and prevents angiogenesis, indicated for treatment of various types of cancer including cervical cancer, ovarian cancer, lung cancer, colorectal cancer, renal cell carcinoma, and breast cancer.

bionovis.com.br
+1 more record
Core offering1 text field

Bionovis manufactures and commercializes biological and biosimilar medicines using mammalian cell culture technology. Its portfolio includes monoclonal antibodies, fusion proteins, and cytokines developed for cancer, autoimmune, neurological, and hematological conditions, supplied primarily to the Brazilian public healthcare system (SUS), the private market, and contract manufacturing (CMO) clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Impacted over 1 million patients with more than 19 million vials and syringes of biopharmaceuticals
+2 more records
Product overview1 text field

Bionovis is a Brazilian pharmaceutical biotechnology company pioneering in the production and commercialization of biological and biosimilar medicines. Founded in 2012 as a joint venture of Aché, EMS, Hypera Pharma, and União Química laboratories, the company operates in research, development, manufacturing, and commercialization of highly complex biopharmaceuticals. Their portfolio includes monoclonal antibodies (bevacizumab/Bevanovis®, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim/Pegtima®). The company also develops proprietary pipeline candidates (BNV-007, BNV-008) and produces biosimilar versions of reference biologics for the Brazilian public healthcare system (SUS) through technology transfer agreements with global partners including Samsung Bioepis, Sandoz, Dr. Reddy's, and Biocon. Products serve therapeutic areas including oncology, immunology, neurology, ophthalmology, and hematology.

Product and service1 record
1Bevanovis (bevacizumab)
Description

Biosimilar of bevacizumab, a monoclonal antibody targeting VEGF used in oncology. Supplied to the Brazilian public healthcare system (SUS) and private market for treatment of colorectal, lung, and other cancers.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

Bionovis, BahiaFarma, and Biocon signed an MoU at the Ficci India-Brazil Business Forum for developing Pertuzumab, a drug for HER-2 metastatic breast cancer. The agreement also promotes collaboration on rare diseases, oncology, and immunosuppressants for public health. Signed in the presence of Brazilian President Luiz Inacio Lula da Silva and Indian Commerce Minister Piyush Goyal.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-23
Description

BahiaFarma, Biocon, and Bionovis signed an MoU for developing Pertuzumab for HER-2 metastatic breast cancer treatment, with collaboration on rare diseases, oncology, and immunosuppressants for public health.

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreements for etanercept, trastuzumab, aflibercept, bevacizumab, and eculizumab biosimilars for supply through SUS (Brazilian Public Healthcare System).

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreement for infliximab (originator biologic) and golimumab for supply through SUS.

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreement for interferon beta-1a biopharmaceutical for supply through SUS.

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreement for rituximab biosimilar for supply through SUS.

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreement for adalimumab biosimilar for supply through SUS.

Strategic tierCoreTypeTechnology or Integration
Description

Technology transfer agreement for nivolumab biosimilar for supply through SUS.

9Bio-Manguinhos/FIOCRUZ
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with leading Brazilian public laboratory for development and supply of biological medicines through SUS.

bionovis.com.br
10FUNED
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with public laboratory for development and supply of biological medicines through SUS.

bionovis.com.br
11INTAS
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.

bionovis.com.br
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Commercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1Bio-Manguinhos (Fiocruz)
TypeRegional player
Description

Bio-Manguinhos is the Brazilian public laboratory arm of Fiocruz and a strategic partner of Bionovis for biological medicine development and SUS supply. Directly comparable as a domestic Brazilian biopharmaceutical manufacturer operating through PDP arrangements.

TypeDirect peer
Description

mAbxience is a Spanish-headquartered biosimilar developer and manufacturer of monoclonal antibodies. Bionovis's private-market distribution partner in Brazil; comparable as an emerging biosimilar manufacturer focused on mAb products for global markets.

3Eurofarma Laboratórios
TypeRegional player
Description

Eurofarma is a major Brazilian pharmaceutical company with growing biotechnology investments. Comparable as a Brazilian pharma expanding into domestic biologics manufacturing and competing for PDP awards and private market share.

TypeDirect peer
Description

Celltrion is a South Korea-based biosimilar pioneer with approved products across oncology, immunology, and ophthalmology. Directly comparable as a mammalian-cell-based biosimilar manufacturer with strong regulatory and commercial capabilities.

TypeBroad incumbent
Description

Amgen is a global biotechnology incumbent that both originates biologics and produces biosimilars. Comparable as a large-scale biomanufacturer with a portfolio spanning oncology, inflammation, and hematology — directly overlapping therapeutic areas with Bionovis.

TypeDirect peer
Description

Samsung Bioepis is a major biosimilar manufacturer and one of Bionovis's core technology transfer partners (etanercept, trastuzumab, aflibercept, bevacizumab, eculizumab). Directly comparable as a biosimilar-focused biopharma with global development and manufacturing footprint.

TypeDirect peer
Description

Dr. Reddy's is an Indian multinational with a biosimilars portfolio (nivolumab technology partner to Bionovis). Comparable as an integrated pharma manufacturer with biosimilar development and emerging-markets commercialization capabilities.

8Sandoz
TypeDirect peer
Description

Sandoz is the global biosimilars leader and a Novartis division. Technology transfer partner for rituximab biosimilar at Bionovis; operates large-scale biosimilar manufacturing and commercial infrastructure across multiple therapeutic areas.

TypeDirect peer
Description

Fresenius Kabi is a global biopharma player with a growing biosimilars franchise. Technology transfer partner to Bionovis for adalimumab; comparable as an integrated manufacturer developing and commercializing biosimilars globally.

TypeDirect peer
Description

Biocon Biologics is a leading global biosimilar developer and manufacturer. Partner of Bionovis for pertuzumab development; directly comparable as a vertically integrated biosimilar company serving emerging and regulated markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bionovis

Biopharmaceuticalsbionovis.com.br

Bionovis is a Brazilian pharmaceutical biotech (founded 2012 as a JV of Aché, EMS, Hypera Pharma, and União Química) that develops and manufactures biological and biosimilar medicines at its ANVISA-certified Valinhos facility, supplying SUS, private healthcare, and CMO clients.

What Bionovis does

Bionovis is a privately held Brazilian pharmaceutical biotechnology company founded in 2012 as a joint venture of four domestic laboratories — Aché, EMS, Hypera Pharma, and União Química. The company develops and manufactures biological and biosimilar medicines using mammalian cell culture technology at an industrial-scale facility in Valinhos, São Paulo, which houses a pilot plant (bioreactors up to 200 L), a quality control laboratory, and three production lines (one continuous perfusion, two fed-batch using single-use reactors) totaling more than 20,000 L of bioreactor volume and capacity to produce up to 250 kg of protein per year across ten biopharmaceuticals. Its marketed portfolio spans monoclonal antibodies (bevacizumab, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim), addressing oncology, autoimmune disease, neurology, ophthalmology, and hematology.

The revenue model rests on three pillars: (i) supply of biosimilars to the Brazilian public healthcare system (SUS) under Productive Development Partnerships (PDPs) with the Ministry of Health, technology-transfer-licensed from global originators (Samsung Bioepis, Sandoz, Biocon, Dr. Reddy's, Fresenius Kabi, J&J/Janssen, Merck); (ii) private-market commercialization through commercial partnerships with INTAS and mAbxience; and (iii) contract manufacturing organization (CMO) services at the Valinhos plant. Notable commercial brands include Bevanovis® (bevacizumab, launched 2025) and Pegtima® (pegfilgrastim, launched 2023). The company is ANVISA-certified, claims more than 1 million patients impacted and 19 million vials/syringes delivered cumulatively since founding, and is pursuing in-house pipeline candidates BNV-007 and BNV-008 alongside new 2026 partnerships for pertuzumab and additional biosimilars targeting expansion into Latin America and other regulated markets.

Bionovis firmographics

Firmographics
Name
Bionovis
Legal name
BIONOVIS S/A – COMPANHIA BRASILEIRA DE BIOTECNOLOGIA FARMACÊUTICA
Website
https://bionovis.com.br
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
251–500 employees
Short description
Bionovis is a Brazilian pharmaceutical biotech (founded 2012 as a JV of Aché, EMS, Hypera Pharma, and União Química) that develops and manufactures biological and biosimilar medicines at its ANVISA-certified Valinhos facility, supplying SUS, private healthcare, and CMO clients.
Ownership category
akta.pro rank

Bionovis industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAFAA
Monoclonal Antibody (mAb) Biosimilars
SECONDARYHLAIAFAL
Other Recombinant Protein Biosimilars (non-mAb, non-hormone)

Keywords

  • Biological medicines
  • Biosimilar production
  • Monoclonal antibodies
  • Pharmaceutical manufacturing
  • Contract manufacturing

Where Bionovis is headquartered

Location

Headquarters

HQ city
Valinhos
HQ country
Brazil
HQ region
Latin America

Offices1 record

Markets served

Bionovis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Technology or R&D, Personnel, Supply Chain, Marketing or Sales

Revenue model

  1. Public Healthcare Product Sales (SUS): Bionovis supplies biological and biosimilar medicines to the Brazilian public healthcare system (SUS) through Productive Development Partnerships (PDPs) with the Ministry of Health. Products include infliximab, interferon beta-1a, etanercept, trastuzumab, golimumab, rituximab, adalimumab, bevacizumab, nivolumab, pertuzumab, aflibercept, eculizumab, and pegfilgrastim.
  2. Private Market Commercialization: Commercial partnerships in the private sector through INTAS and mAbxience for distribution and sale of biopharmaceutical products in the Brazilian private market.
  3. Contract Manufacturing (CMO Services): Bionovis offers contract manufacturing organization services at its industrial plant in Valinhos, São Paulo, enabling pharmaceutical companies to outsource large-scale manufacturing of biopharmaceuticals or production of clinical batches for scientific trials.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Bionovis product offering

Product offering

Core offering

Bionovis manufactures and commercializes biological and biosimilar medicines using mammalian cell culture technology. Its portfolio includes monoclonal antibodies, fusion proteins, and cytokines developed for cancer, autoimmune, neurological, and hematological conditions, supplied primarily to the Brazilian public healthcare system (SUS), the private market, and contract manufacturing (CMO) clients.

Product overview

Bionovis is a Brazilian pharmaceutical biotechnology company pioneering in the production and commercialization of biological and biosimilar medicines. Founded in 2012 as a joint venture of Aché, EMS, Hypera Pharma, and União Química laboratories, the company operates in research, development, manufacturing, and commercialization of highly complex biopharmaceuticals. Their portfolio includes monoclonal antibodies (bevacizumab/Bevanovis®, trastuzumab, rituximab, pertuzumab, nivolumab, adalimumab, etanercept, golimumab, infliximab), fusion proteins (aflibercept), cytokines (interferon beta-1a), and hematology products (eculizumab, pegfilgrastim/Pegtima®). The company also develops proprietary pipeline candidates (BNV-007, BNV-008) and produces biosimilar versions of reference biologics for the Brazilian public healthcare system (SUS) through technology transfer agreements with global partners including Samsung Bioepis, Sandoz, Dr. Reddy's, and Biocon. Products serve therapeutic areas including oncology, immunology, neurology, ophthalmology, and hematology.

Differentiator

Problem solved

Functional benefit

Brands

  • Bevanovis (bevacizumab): Bevanovis is a monoclonal antibody that inhibits VEGF and prevents angiogenesis, indicated for treatment of various types of cancer including cervical cancer, ovarian cancer, lung cancer, colorectal cancer, renal cell carcinoma, and breast cancer.
  • Pegtima (pegfilgrastim)

Products and services

  • Bevanovis (bevacizumab) Biosimilar of bevacizumab, a monoclonal antibody targeting VEGF used in oncology. Supplied to the Brazilian public healthcare system (SUS) and private market for treatment of colorectal, lung, and other cancers.

Quantifiable outcome

  • Impacted over 1 million patients with more than 19 million vials and syringes of biopharmaceuticals
  • +2 more outcomes

Companies that use Bionovis

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Bionovis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Bionovis partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core.

  • Biocon Biologics LtdcoreStrategic or Co-development Partner · 23 February 2026Bionovis, BahiaFarma, and Biocon signed an MoU at the Ficci India-Brazil Business Forum for developing Pertuzumab, a drug for HER-2 metastatic breast cancer. The agreement also promotes collaboration on rare diseases, oncology, and immunosuppressants for public health. Signed in the presence of Brazilian President Luiz Inacio Lula da Silva and Indian Commerce Minister Piyush Goyal.
  • BahiaFarmacoreStrategic or Co-development Partner · 23 February 2026BahiaFarma, Biocon, and Bionovis signed an MoU for developing Pertuzumab for HER-2 metastatic breast cancer treatment, with collaboration on rare diseases, oncology, and immunosuppressants for public health.
  • Samsung BioepiscoreTechnology or IntegrationTechnology transfer agreements for etanercept, trastuzumab, aflibercept, bevacizumab, and eculizumab biosimilars for supply through SUS (Brazilian Public Healthcare System).
  • Janssen-Cilag (Johnson & Johnson)coreTechnology or IntegrationTechnology transfer agreement for infliximab (originator biologic) and golimumab for supply through SUS.
  • MerckcoreTechnology or IntegrationTechnology transfer agreement for interferon beta-1a biopharmaceutical for supply through SUS.
  • SandozcoreTechnology or IntegrationTechnology transfer agreement for rituximab biosimilar for supply through SUS.
  • Fresenius KabicoreTechnology or IntegrationTechnology transfer agreement for adalimumab biosimilar for supply through SUS.
  • Dr. Reddy'scoreTechnology or IntegrationTechnology transfer agreement for nivolumab biosimilar for supply through SUS.
  • Bio-Manguinhos/FIOCRUZcoreStrategic or Co-development PartnerPartnership with leading Brazilian public laboratory for development and supply of biological medicines through SUS.
  • FUNEDcoreStrategic or Co-development PartnerPartnership with public laboratory for development and supply of biological medicines through SUS.
  • INTAScoreChannel Partner/ Reseller/ DistributorCommercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.
  • mAbxiencecoreChannel Partner/ Reseller/ DistributorCommercial partnership for distribution and sale of biopharmaceuticals in the Brazilian private market.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Bionovis competitors and assessment

Company assessment

Regional players

  • Bio-Manguinhos (Fiocruz): Bio-Manguinhos is the Brazilian public laboratory arm of Fiocruz and a strategic partner of Bionovis for biological medicine development and SUS supply. Directly comparable as a domestic Brazilian biopharmaceutical manufacturer operating through PDP arrangements.
  • Eurofarma Laboratórios: Eurofarma is a major Brazilian pharmaceutical company with growing biotechnology investments. Comparable as a Brazilian pharma expanding into domestic biologics manufacturing and competing for PDP awards and private market share.

Direct peers

  • mAbxience: mAbxience is a Spanish-headquartered biosimilar developer and manufacturer of monoclonal antibodies. Bionovis's private-market distribution partner in Brazil; comparable as an emerging biosimilar manufacturer focused on mAb products for global markets.
  • Celltrion: Celltrion is a South Korea-based biosimilar pioneer with approved products across oncology, immunology, and ophthalmology. Directly comparable as a mammalian-cell-based biosimilar manufacturer with strong regulatory and commercial capabilities.
  • Samsung Bioepis: Samsung Bioepis is a major biosimilar manufacturer and one of Bionovis's core technology transfer partners (etanercept, trastuzumab, aflibercept, bevacizumab, eculizumab). Directly comparable as a biosimilar-focused biopharma with global development and manufacturing footprint.
  • Dr. Reddy's Laboratories: Dr. Reddy's is an Indian multinational with a biosimilars portfolio (nivolumab technology partner to Bionovis). Comparable as an integrated pharma manufacturer with biosimilar development and emerging-markets commercialization capabilities.
  • Sandoz: Sandoz is the global biosimilars leader and a Novartis division. Technology transfer partner for rituximab biosimilar at Bionovis; operates large-scale biosimilar manufacturing and commercial infrastructure across multiple therapeutic areas.
  • Fresenius Kabi: Fresenius Kabi is a global biopharma player with a growing biosimilars franchise. Technology transfer partner to Bionovis for adalimumab; comparable as an integrated manufacturer developing and commercializing biosimilars globally.
  • Biocon Biologics: Biocon Biologics is a leading global biosimilar developer and manufacturer. Partner of Bionovis for pertuzumab development; directly comparable as a vertically integrated biosimilar company serving emerging and regulated markets.

Broad incumbents

  • Amgen: Amgen is a global biotechnology incumbent that both originates biologics and produces biosimilars. Comparable as a large-scale biomanufacturer with a portfolio spanning oncology, inflammation, and hematology — directly overlapping therapeutic areas with Bionovis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Bionovis social profiles

Digital presence

Bionovis compliance and trust

Trust signal

Compliance2 records

Bionovis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bionovis leadership team

Management profile

Number of profiles

Bionovis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bionovis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bionovis

What does Bionovis do?

Bionovis manufactures and commercializes biological and biosimilar medicines using mammalian cell culture technology. Its portfolio includes monoclonal antibodies, fusion proteins, and cytokines developed for cancer, autoimmune, neurological, and hematological conditions, supplied primarily to the Brazilian public healthcare system (SUS), the private market, and contract manufacturing (CMO) clients.

Is Bionovis a public or private company?

Bionovis is a private company. It is classified as corporate owned and is currently operating.

When was Bionovis founded?

Bionovis was founded in 2012. It employs 251 to 500 people.

Where is Bionovis based?

Bionovis is headquartered in Valinhos, Brazil, in the Latin America region.

How does Bionovis make money?

Three revenue lines are on record. Public Healthcare Product Sales (SUS) is the primary driver. The others are private Market Commercialization and contract Manufacturing (CMO Services).

Who are Bionovis's main competitors?

Regional players on record are Bio-Manguinhos (Fiocruz) and Eurofarma Laboratórios. Direct peers are mAbxience, Celltrion, Samsung Bioepis, Dr. Reddy's Laboratories, Sandoz, Fresenius Kabi and Biocon Biologics. Amgen is listed as a broad incumbent.

Does Bionovis have an API?

No public API is recorded for Bionovis.

What industry is Bionovis in?

Bionovis's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAFAA, Monoclonal Antibody (mAb) Biosimilars, with a secondary code of HLAIAFAL, Other Recombinant Protein Biosimilars (non-mAb, non-hormone). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business StandardBiocon share price rises 3% after block deal, Pertuzumab deal in BrazilBiocon shares rose 3% to ₹403.95 after a pre-market block deal of 16.6 million shares. The company also signed a partnership with Bahiafarma and Bionovis for Pertuzumab in Brazil under the PDP programme. Analysts see ₹395-400 as support, with upside toward ₹430.The Times of IndiaBiocon signs 10-year Brazil supply deal for Pertuzumab breast cancer drugBiocon signed a 10-year supply contract in Brazil for Pertuzumab, a breast cancer drug, with Bahiafarma and Bionovis. The consortium received 100% allocation under Brazil's PDP, granting exclusive access to the public healthcare market, which accounts for about 70% of demand. The deal includes phased localisation of production in Brazil.TradingViewNews by CNBC TV18 on TradingView, 2026-09-08Biocon secured a 10-year supply contract for Pertuzumab in Brazil with Bahiafarma and Bionovis, gaining 100% allocation under the PDP programme. The deal grants exclusive access to Brazil's public healthcare market, which accounts for about 70% of demand. Shares rose 1.1% to ₹395.6 on Tuesday.https://www.outlookbusiness.com/BahiaFarma, Biocon, Bionovis Inks MoU in Pharma Sector – Outlook BusinessBahiaFarma, Biocon Biologics Ltd, and Bionovis signed an MoU at the Ficci India-Brazil Business Forum for developing Pertuzumab, a drug for HER-2 metastatic breast cancer, in the presence of Brazilian President Luiz Inacio Lula da Silva and Indian Commerce Minister Piyush Goyal. Separately, NMDC Ltd, Vale SA, and Adani Gangavaram Port Ltd signed another MoU to create an iron ore blending facility under a Special Economic Zone at the Port of Gangavaram, with each party handling distinct parts of the supply chain from ore sourcing to port operations.https://www.outlookbusiness.com/BahiaFarma, Biocon, Bionovis Inks MoU in Pharma Sector – Outlook BusinessBahiaFarma, Biocon, and Bionovis signed an MoU to develop a medicine for HER-2 metastatic breast cancer, in the presence of Brazilian President Luiz Inacio Lula da Silva. The agreement also promotes collaboration on rare diseases, oncology, and immunosuppressants for public health, alongside other partnerships involving NMDC Ltd, Vale SA, and Adani Gangavaram Port Ltd.